Back to top

gene-editing: Archive

Zacks Equity Research

BEAM Focuses on Developing Gene Drug for Growth

While BEAM's pipeline candidates are in early-stage clinical studies, their development is progressing well. Collaborations are a primary source of revenues in the absence of a marketed product.

PFEPositive Net Change VRTXPositive Net Change BEAMNegative Net Change CRSPNegative Net Change

Zacks Equity Research

QIAGEN (QGEN) Broadens QuantiFERON Line With EBV RUO Assay

QIAGEN (QGEN) notes that T-cells are vital in combatting viral infections and the QuantiFERON-EBV RUO assay focuses on measuring the T-cell response to EBV.

ALGNNegative Net Change HAEPositive Net Change QGENPositive Net Change QTRXPositive Net Change

Zacks Equity Research

Intellia (NTLA), Regeneron Expand Deal for Gene-Editing Therapies

Intellia (NTLA) expands partnership with Regeneron, to develop potential treatments for neurological and muscular diseases.

REGNNegative Net Change ANIKNegative Net Change NTLANegative Net Change ANVSNegative Net Change

Zacks Equity Research

Exact Sciences (EXAS) Aided by Innovation, Strategic Buyouts

Exact Sciences (EXAS) is planning several key milestones to bring six innovative cancer diagnostics from its pipeline to patients in need.

BSXPositive Net Change HAEPositive Net Change EXASPositive Net Change QTRXPositive Net Change

Zacks Equity Research

Kinnate Biopharma (KNTE) Falls 40% in a Month: Here's Why

Kinnate Biopharma (KNTE) plunges 40% in a month for the decision to streamline its pipeline to one clinical candidate as part of its reprioritization efforts and slash workforce by 70%.

PFEPositive Net Change CORTNegative Net Change BTTXNo Net Change